Rate Video

ESMO WCGIC 2020 | Nivolumab for CCA

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer Antibodies FOLFOX Nivolumab

ABC-06 Immuno-Oncology

Richard Kim, MD, of the Moffitt Cancer Center, Tampa, FL, describes Phase II results of nivolumab in patients with advanced, refractory cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Lenvatinib and pembrolizumab in microsatellite stable CRC

Richard Kim • 14 Jan 2021

SWOG S1310: trametinib vs 5-FU/capecitabine in refractory advanced biliary cancer

Richard Kim • 2 Jul 2020

Liposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTC

Richard Kim • 10 Jun 2021

80mg regorafenib plus pembrolizumab for 1L HCC

Richard Kim • 10 Jun 2021

Related Videos

Novel developments in HCC treatment

COVID-19 & the management of cancer patients

Alberto F. Sobrero

HER-2 conversion: a phenomenon in trastuzumab resistance

The gut microbiome: role in causing and detecting colorectal cancer